Sardona Therapeutics

Sardona Therapeutics is a preclinical biotechnology company building the leading platform to develop small molecule drugs that target RNA-binding proteins in the spliceosome, and provide patients with therapy-resistant cancers novel treatment options. Sardona is advancing a robust pipeline of multiple, internally-developed programs, including the lead program, that has particular activity in mTORC1-pathway activated breast cancers and other solid tumor indications.